Biocryst Pharmaceuticals (BCRX) Non-Current Debt (2011 - 2026)

Biocryst Pharmaceuticals' Non-Current Debt history runs 16 years deep, the most recent figure standing at $395.2 million for Q1 2026.

• Quarterly Non-Current Debt rose 25.3% year-over-year to $395.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $395.2 million (up 25.3% YoY) and the FY2024 annual result came in at $314.9 million, up 3.84% from the prior year.
• Non-Current Debt was $395.2 million for Q1 2026 at Biocryst Pharmaceuticals, up from $194.4 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $395.2 million in Q1 2026 and bottomed at $140.2 million in Q1 2022.
• A 5-year average of $266.7 million and a median of $295.6 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2023 — Non-Current Debt soared 102.87% — and 2025, when it sank 38.17%.
• Biocryst Pharmaceuticals' Non-Current Debt stood at $231.6 million in 2022, then surged by 30.92% to $303.2 million in 2023, then climbed by 3.84% to $314.9 million in 2024, then sank by 38.27% to $194.4 million in 2025, then soared by 103.33% to $395.2 million in 2026.
• Business Quant data shows BCRX's Non-Current Debt at $395.2 million in Q1 2026, $194.4 million in Q3 2025, and $242.8 million in Q2 2025.